366. Optimization of a Surrogate Assay for Efficacy of a Malaria Transmission Blocking Vaccine Article Swipe
Cristina Meehan
,
Cristina Meehan
,
Patrick Duffy
,
Jonathan P. Renn
,
Irfan Zaidi
·
YOU?
·
· 2022
· Open Access
·
· DOI: https://doi.org/10.1093/ofid/ofac492.444
YOU?
·
· 2022
· Open Access
·
· DOI: https://doi.org/10.1093/ofid/ofac492.444
Background An estimated 241 million malaria cases and 627,000 malaria deaths occurred worldwide in 2020. Efforts to develop a higher efficacy malaria vaccine are a global priority, but parasites pose a complex biological puzzle for vaccine development. Innovative vaccine strategies include transmission blocking vaccines (TBV) that target the mosquito stages of parasite development to interrupt parasite transmission. The current leading TBV called Pfs230D1-EPA targets Pfs230, a Plasmodium falciparum gamete surface protein that mediates binding of microgametes to red blood cells. Antibodies against Pfs230 bind and lyse gametes in a complement-dependent manner to block transmission. Methods Here, we are exploiting a panel of human monoclonal antibodies (hmAb) generated from human volunteers who received Pfs230D1-EPA formulated in Alhydrogel or AS01 adjuvants, to develop a competitive ELISA platform. This assay will quantify epitope-specific serum antibodies along with their features and effector functions, expanding the conventionally used functional assay of standard membrane feeding (SMFA). Results The competitive ELISA is being developed with single-chain variable fragments (ScFv) to define epitope-specific binding of antibodies in sera from vaccinated individuals. Sera of human volunteers from trials in Mali, Africa will be assayed to assess epitope-specific serum antibody binding that is competed off in the presence of saturating levels of ScFv. Preliminary optimization of the competitive assay has shown concentration-dependent epitope-specific competition between ScFv and hmAbs and confirmation of ScFv binding to Pfs230D1 antigen. Conclusion Further optimization of this assay will characterize the complement-binding and isotype/subclass-specific features of epitope-specific antibodies. These efforts will lay the foundations for standardized assays that can assess correlates of vaccine efficacy and durability of this leading TBV. Disclosures All Authors: No reported disclosures.
Related Topics
Concepts
Epitope
Plasmodium falciparum
Antibody
Virology
Monoclonal antibody
Malaria
Antigen
Biology
Epitope mapping
Isotype
Immunology
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1093/ofid/ofac492.444
- https://academic.oup.com/ofid/article-pdf/9/Supplement_2/ofac492.444/47890171/ofac492.444.pdf
- OA Status
- gold
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4311747991
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4311747991Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1093/ofid/ofac492.444Digital Object Identifier
- Title
-
366. Optimization of a Surrogate Assay for Efficacy of a Malaria Transmission Blocking VaccineWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2022Year of publication
- Publication date
-
2022-12-01Full publication date if available
- Authors
-
Cristina Meehan, Cristina Meehan, Patrick Duffy, Jonathan P. Renn, Irfan ZaidiList of authors in order
- Landing page
-
https://doi.org/10.1093/ofid/ofac492.444Publisher landing page
- PDF URL
-
https://academic.oup.com/ofid/article-pdf/9/Supplement_2/ofac492.444/47890171/ofac492.444.pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://academic.oup.com/ofid/article-pdf/9/Supplement_2/ofac492.444/47890171/ofac492.444.pdfDirect OA link when available
- Concepts
-
Epitope, Plasmodium falciparum, Antibody, Virology, Monoclonal antibody, Malaria, Antigen, Biology, Epitope mapping, Isotype, ImmunologyTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4311747991 |
|---|---|
| doi | https://doi.org/10.1093/ofid/ofac492.444 |
| ids.doi | https://doi.org/10.1093/ofid/ofac492.444 |
| ids.openalex | https://openalex.org/W4311747991 |
| fwci | 0.0 |
| type | article |
| title | 366. Optimization of a Surrogate Assay for Efficacy of a Malaria Transmission Blocking Vaccine |
| biblio.issue | Supplement_2 |
| biblio.volume | 9 |
| biblio.last_page | |
| biblio.first_page | |
| topics[0].id | https://openalex.org/T10091 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9868999719619751 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2739 |
| topics[0].subfield.display_name | Public Health, Environmental and Occupational Health |
| topics[0].display_name | Malaria Research and Control |
| topics[1].id | https://openalex.org/T12576 |
| topics[1].field.id | https://openalex.org/fields/13 |
| topics[1].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[1].score | 0.944100022315979 |
| topics[1].domain.id | https://openalex.org/domains/1 |
| topics[1].domain.display_name | Life Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/1312 |
| topics[1].subfield.display_name | Molecular Biology |
| topics[1].display_name | vaccines and immunoinformatics approaches |
| topics[2].id | https://openalex.org/T10166 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9329000115394592 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2739 |
| topics[2].subfield.display_name | Public Health, Environmental and Occupational Health |
| topics[2].display_name | Mosquito-borne diseases and control |
| is_xpac | False |
| apc_list.value | 3064 |
| apc_list.currency | USD |
| apc_list.value_usd | 3064 |
| apc_paid.value | 3064 |
| apc_paid.currency | USD |
| apc_paid.value_usd | 3064 |
| concepts[0].id | https://openalex.org/C195616568 |
| concepts[0].level | 3 |
| concepts[0].score | 0.8595649003982544 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q128711 |
| concepts[0].display_name | Epitope |
| concepts[1].id | https://openalex.org/C2778371730 |
| concepts[1].level | 3 |
| concepts[1].score | 0.6751307249069214 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q311383 |
| concepts[1].display_name | Plasmodium falciparum |
| concepts[2].id | https://openalex.org/C159654299 |
| concepts[2].level | 2 |
| concepts[2].score | 0.6525007486343384 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q79460 |
| concepts[2].display_name | Antibody |
| concepts[3].id | https://openalex.org/C159047783 |
| concepts[3].level | 1 |
| concepts[3].score | 0.600632905960083 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q7215 |
| concepts[3].display_name | Virology |
| concepts[4].id | https://openalex.org/C542903549 |
| concepts[4].level | 3 |
| concepts[4].score | 0.6004091501235962 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q422248 |
| concepts[4].display_name | Monoclonal antibody |
| concepts[5].id | https://openalex.org/C2778048844 |
| concepts[5].level | 2 |
| concepts[5].score | 0.5980614423751831 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q12156 |
| concepts[5].display_name | Malaria |
| concepts[6].id | https://openalex.org/C147483822 |
| concepts[6].level | 2 |
| concepts[6].score | 0.4880446493625641 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q103537 |
| concepts[6].display_name | Antigen |
| concepts[7].id | https://openalex.org/C86803240 |
| concepts[7].level | 0 |
| concepts[7].score | 0.4783434569835663 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q420 |
| concepts[7].display_name | Biology |
| concepts[8].id | https://openalex.org/C2781241564 |
| concepts[8].level | 4 |
| concepts[8].score | 0.44208768010139465 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q1347450 |
| concepts[8].display_name | Epitope mapping |
| concepts[9].id | https://openalex.org/C2777991845 |
| concepts[9].level | 4 |
| concepts[9].score | 0.4252268970012665 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q2396793 |
| concepts[9].display_name | Isotype |
| concepts[10].id | https://openalex.org/C203014093 |
| concepts[10].level | 1 |
| concepts[10].score | 0.4251406490802765 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q101929 |
| concepts[10].display_name | Immunology |
| keywords[0].id | https://openalex.org/keywords/epitope |
| keywords[0].score | 0.8595649003982544 |
| keywords[0].display_name | Epitope |
| keywords[1].id | https://openalex.org/keywords/plasmodium-falciparum |
| keywords[1].score | 0.6751307249069214 |
| keywords[1].display_name | Plasmodium falciparum |
| keywords[2].id | https://openalex.org/keywords/antibody |
| keywords[2].score | 0.6525007486343384 |
| keywords[2].display_name | Antibody |
| keywords[3].id | https://openalex.org/keywords/virology |
| keywords[3].score | 0.600632905960083 |
| keywords[3].display_name | Virology |
| keywords[4].id | https://openalex.org/keywords/monoclonal-antibody |
| keywords[4].score | 0.6004091501235962 |
| keywords[4].display_name | Monoclonal antibody |
| keywords[5].id | https://openalex.org/keywords/malaria |
| keywords[5].score | 0.5980614423751831 |
| keywords[5].display_name | Malaria |
| keywords[6].id | https://openalex.org/keywords/antigen |
| keywords[6].score | 0.4880446493625641 |
| keywords[6].display_name | Antigen |
| keywords[7].id | https://openalex.org/keywords/biology |
| keywords[7].score | 0.4783434569835663 |
| keywords[7].display_name | Biology |
| keywords[8].id | https://openalex.org/keywords/epitope-mapping |
| keywords[8].score | 0.44208768010139465 |
| keywords[8].display_name | Epitope mapping |
| keywords[9].id | https://openalex.org/keywords/isotype |
| keywords[9].score | 0.4252268970012665 |
| keywords[9].display_name | Isotype |
| keywords[10].id | https://openalex.org/keywords/immunology |
| keywords[10].score | 0.4251406490802765 |
| keywords[10].display_name | Immunology |
| language | en |
| locations[0].id | doi:10.1093/ofid/ofac492.444 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S2735126445 |
| locations[0].source.issn | 2328-8957 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 2328-8957 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | Open Forum Infectious Diseases |
| locations[0].source.host_organization | https://openalex.org/P4310311648 |
| locations[0].source.host_organization_name | Oxford University Press |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310311648 |
| locations[0].license | cc-by |
| locations[0].pdf_url | https://academic.oup.com/ofid/article-pdf/9/Supplement_2/ofac492.444/47890171/ofac492.444.pdf |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Open Forum Infectious Diseases |
| locations[0].landing_page_url | https://doi.org/10.1093/ofid/ofac492.444 |
| locations[1].id | pmh:oai:pubmedcentral.nih.gov:9752217 |
| locations[1].is_oa | True |
| locations[1].source.id | https://openalex.org/S2764455111 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed Central |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | other-oa |
| locations[1].pdf_url | |
| locations[1].version | submittedVersion |
| locations[1].raw_type | Text |
| locations[1].license_id | https://openalex.org/licenses/other-oa |
| locations[1].is_accepted | False |
| locations[1].is_published | False |
| locations[1].raw_source_name | Open Forum Infect Dis |
| locations[1].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/9752217 |
| indexed_in | crossref, doaj |
| authorships[0].author.id | https://openalex.org/A5079635913 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-5165-9521 |
| authorships[0].author.display_name | Cristina Meehan |
| authorships[0].countries | US |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I1299303238, https://openalex.org/I4210134534 |
| authorships[0].affiliations[0].raw_affiliation_string | National Institutes of Health, National Institute of Allergy and Infectious Diseases , Bethesda, Maryland |
| authorships[0].institutions[0].id | https://openalex.org/I4210134534 |
| authorships[0].institutions[0].ror | https://ror.org/043z4tv69 |
| authorships[0].institutions[0].type | facility |
| authorships[0].institutions[0].lineage | https://openalex.org/I1299022934, https://openalex.org/I1299303238, https://openalex.org/I4210134534 |
| authorships[0].institutions[0].country_code | US |
| authorships[0].institutions[0].display_name | National Institute of Allergy and Infectious Diseases |
| authorships[0].institutions[1].id | https://openalex.org/I1299303238 |
| authorships[0].institutions[1].ror | https://ror.org/01cwqze88 |
| authorships[0].institutions[1].type | government |
| authorships[0].institutions[1].lineage | https://openalex.org/I1299022934, https://openalex.org/I1299303238 |
| authorships[0].institutions[1].country_code | US |
| authorships[0].institutions[1].display_name | National Institutes of Health |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Cristina Meehan |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | National Institutes of Health, National Institute of Allergy and Infectious Diseases , Bethesda, Maryland |
| authorships[1].author.id | https://openalex.org/A5079635913 |
| authorships[1].author.orcid | https://orcid.org/0000-0002-5165-9521 |
| authorships[1].author.display_name | Cristina Meehan |
| authorships[1].countries | US |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I1299303238, https://openalex.org/I4210134534 |
| authorships[1].affiliations[0].raw_affiliation_string | National Institutes of Health, National Institute of Allergy and Infectious Diseases , Bethesda, Maryland |
| authorships[1].institutions[0].id | https://openalex.org/I4210134534 |
| authorships[1].institutions[0].ror | https://ror.org/043z4tv69 |
| authorships[1].institutions[0].type | facility |
| authorships[1].institutions[0].lineage | https://openalex.org/I1299022934, https://openalex.org/I1299303238, https://openalex.org/I4210134534 |
| authorships[1].institutions[0].country_code | US |
| authorships[1].institutions[0].display_name | National Institute of Allergy and Infectious Diseases |
| authorships[1].institutions[1].id | https://openalex.org/I1299303238 |
| authorships[1].institutions[1].ror | https://ror.org/01cwqze88 |
| authorships[1].institutions[1].type | government |
| authorships[1].institutions[1].lineage | https://openalex.org/I1299022934, https://openalex.org/I1299303238 |
| authorships[1].institutions[1].country_code | US |
| authorships[1].institutions[1].display_name | National Institutes of Health |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Cristina Meehan |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | National Institutes of Health, National Institute of Allergy and Infectious Diseases , Bethesda, Maryland |
| authorships[2].author.id | https://openalex.org/A5003638415 |
| authorships[2].author.orcid | |
| authorships[2].author.display_name | Patrick Duffy |
| authorships[2].countries | US |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I1299303238, https://openalex.org/I4210134534 |
| authorships[2].affiliations[0].raw_affiliation_string | National Institutes of Health, National Institute of Allergy and Infectious Diseases , Bethesda, Maryland |
| authorships[2].institutions[0].id | https://openalex.org/I4210134534 |
| authorships[2].institutions[0].ror | https://ror.org/043z4tv69 |
| authorships[2].institutions[0].type | facility |
| authorships[2].institutions[0].lineage | https://openalex.org/I1299022934, https://openalex.org/I1299303238, https://openalex.org/I4210134534 |
| authorships[2].institutions[0].country_code | US |
| authorships[2].institutions[0].display_name | National Institute of Allergy and Infectious Diseases |
| authorships[2].institutions[1].id | https://openalex.org/I1299303238 |
| authorships[2].institutions[1].ror | https://ror.org/01cwqze88 |
| authorships[2].institutions[1].type | government |
| authorships[2].institutions[1].lineage | https://openalex.org/I1299022934, https://openalex.org/I1299303238 |
| authorships[2].institutions[1].country_code | US |
| authorships[2].institutions[1].display_name | National Institutes of Health |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Patrick Duffy |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | National Institutes of Health, National Institute of Allergy and Infectious Diseases , Bethesda, Maryland |
| authorships[3].author.id | https://openalex.org/A5091242339 |
| authorships[3].author.orcid | |
| authorships[3].author.display_name | Jonathan P. Renn |
| authorships[3].countries | US |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I1299303238, https://openalex.org/I4210134534 |
| authorships[3].affiliations[0].raw_affiliation_string | National Institutes of Health, National Institute of Allergy and Infectious Diseases , Bethesda, Maryland |
| authorships[3].institutions[0].id | https://openalex.org/I4210134534 |
| authorships[3].institutions[0].ror | https://ror.org/043z4tv69 |
| authorships[3].institutions[0].type | facility |
| authorships[3].institutions[0].lineage | https://openalex.org/I1299022934, https://openalex.org/I1299303238, https://openalex.org/I4210134534 |
| authorships[3].institutions[0].country_code | US |
| authorships[3].institutions[0].display_name | National Institute of Allergy and Infectious Diseases |
| authorships[3].institutions[1].id | https://openalex.org/I1299303238 |
| authorships[3].institutions[1].ror | https://ror.org/01cwqze88 |
| authorships[3].institutions[1].type | government |
| authorships[3].institutions[1].lineage | https://openalex.org/I1299022934, https://openalex.org/I1299303238 |
| authorships[3].institutions[1].country_code | US |
| authorships[3].institutions[1].display_name | National Institutes of Health |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Jonathan Renn |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | National Institutes of Health, National Institute of Allergy and Infectious Diseases , Bethesda, Maryland |
| authorships[4].author.id | https://openalex.org/A5050112210 |
| authorships[4].author.orcid | https://orcid.org/0000-0001-9161-2050 |
| authorships[4].author.display_name | Irfan Zaidi |
| authorships[4].countries | US |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I1299303238, https://openalex.org/I4210134534 |
| authorships[4].affiliations[0].raw_affiliation_string | National Institutes of Health, National Institute of Allergy and Infectious Diseases , Bethesda, Maryland |
| authorships[4].institutions[0].id | https://openalex.org/I4210134534 |
| authorships[4].institutions[0].ror | https://ror.org/043z4tv69 |
| authorships[4].institutions[0].type | facility |
| authorships[4].institutions[0].lineage | https://openalex.org/I1299022934, https://openalex.org/I1299303238, https://openalex.org/I4210134534 |
| authorships[4].institutions[0].country_code | US |
| authorships[4].institutions[0].display_name | National Institute of Allergy and Infectious Diseases |
| authorships[4].institutions[1].id | https://openalex.org/I1299303238 |
| authorships[4].institutions[1].ror | https://ror.org/01cwqze88 |
| authorships[4].institutions[1].type | government |
| authorships[4].institutions[1].lineage | https://openalex.org/I1299022934, https://openalex.org/I1299303238 |
| authorships[4].institutions[1].country_code | US |
| authorships[4].institutions[1].display_name | National Institutes of Health |
| authorships[4].author_position | last |
| authorships[4].raw_author_name | Irfan Zaidi |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | National Institutes of Health, National Institute of Allergy and Infectious Diseases , Bethesda, Maryland |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://academic.oup.com/ofid/article-pdf/9/Supplement_2/ofac492.444/47890171/ofac492.444.pdf |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | 366. Optimization of a Surrogate Assay for Efficacy of a Malaria Transmission Blocking Vaccine |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10091 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9868999719619751 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2739 |
| primary_topic.subfield.display_name | Public Health, Environmental and Occupational Health |
| primary_topic.display_name | Malaria Research and Control |
| related_works | https://openalex.org/W3189724180, https://openalex.org/W2471846512, https://openalex.org/W4214932605, https://openalex.org/W3096915742, https://openalex.org/W2393351343, https://openalex.org/W2019166448, https://openalex.org/W4214758967, https://openalex.org/W2331458684, https://openalex.org/W3006433770, https://openalex.org/W2800235700 |
| cited_by_count | 0 |
| locations_count | 2 |
| best_oa_location.id | doi:10.1093/ofid/ofac492.444 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S2735126445 |
| best_oa_location.source.issn | 2328-8957 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 2328-8957 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | Open Forum Infectious Diseases |
| best_oa_location.source.host_organization | https://openalex.org/P4310311648 |
| best_oa_location.source.host_organization_name | Oxford University Press |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310311648 |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | https://academic.oup.com/ofid/article-pdf/9/Supplement_2/ofac492.444/47890171/ofac492.444.pdf |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Open Forum Infectious Diseases |
| best_oa_location.landing_page_url | https://doi.org/10.1093/ofid/ofac492.444 |
| primary_location.id | doi:10.1093/ofid/ofac492.444 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S2735126445 |
| primary_location.source.issn | 2328-8957 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 2328-8957 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | Open Forum Infectious Diseases |
| primary_location.source.host_organization | https://openalex.org/P4310311648 |
| primary_location.source.host_organization_name | Oxford University Press |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310311648 |
| primary_location.license | cc-by |
| primary_location.pdf_url | https://academic.oup.com/ofid/article-pdf/9/Supplement_2/ofac492.444/47890171/ofac492.444.pdf |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Open Forum Infectious Diseases |
| primary_location.landing_page_url | https://doi.org/10.1093/ofid/ofac492.444 |
| publication_date | 2022-12-01 |
| publication_year | 2022 |
| referenced_works_count | 0 |
| abstract_inverted_index.a | 19, 25, 31, 66, 89, 100, 122 |
| abstract_inverted_index.An | 2 |
| abstract_inverted_index.No | 268 |
| abstract_inverted_index.be | 184 |
| abstract_inverted_index.in | 14, 88, 115, 169, 180, 196 |
| abstract_inverted_index.is | 155, 193 |
| abstract_inverted_index.of | 51, 75, 102, 146, 167, 175, 199, 202, 206, 221, 230, 240, 256, 261 |
| abstract_inverted_index.or | 117 |
| abstract_inverted_index.to | 17, 54, 77, 92, 120, 163, 186, 224 |
| abstract_inverted_index.we | 97 |
| abstract_inverted_index.241 | 4 |
| abstract_inverted_index.All | 266 |
| abstract_inverted_index.TBV | 61 |
| abstract_inverted_index.The | 58, 152 |
| abstract_inverted_index.and | 8, 85, 137, 217, 219, 237, 259 |
| abstract_inverted_index.are | 24, 98 |
| abstract_inverted_index.but | 28 |
| abstract_inverted_index.can | 253 |
| abstract_inverted_index.for | 35, 249 |
| abstract_inverted_index.has | 210 |
| abstract_inverted_index.lay | 246 |
| abstract_inverted_index.off | 195 |
| abstract_inverted_index.red | 78 |
| abstract_inverted_index.the | 48, 141, 197, 207, 235, 247 |
| abstract_inverted_index.who | 111 |
| abstract_inverted_index.AS01 | 118 |
| abstract_inverted_index.ScFv | 216, 222 |
| abstract_inverted_index.Sera | 174 |
| abstract_inverted_index.TBV. | 264 |
| abstract_inverted_index.This | 126 |
| abstract_inverted_index.bind | 84 |
| abstract_inverted_index.from | 108, 171, 178 |
| abstract_inverted_index.lyse | 86 |
| abstract_inverted_index.pose | 30 |
| abstract_inverted_index.sera | 170 |
| abstract_inverted_index.that | 46, 72, 192, 252 |
| abstract_inverted_index.this | 231, 262 |
| abstract_inverted_index.used | 143 |
| abstract_inverted_index.will | 128, 183, 233, 245 |
| abstract_inverted_index.with | 134, 158 |
| abstract_inverted_index.(TBV) | 45 |
| abstract_inverted_index.2020. | 15 |
| abstract_inverted_index.ELISA | 124, 154 |
| abstract_inverted_index.Here, | 96 |
| abstract_inverted_index.Mali, | 181 |
| abstract_inverted_index.ScFv. | 203 |
| abstract_inverted_index.These | 243 |
| abstract_inverted_index.along | 133 |
| abstract_inverted_index.assay | 127, 145, 209, 232 |
| abstract_inverted_index.being | 156 |
| abstract_inverted_index.block | 93 |
| abstract_inverted_index.blood | 79 |
| abstract_inverted_index.cases | 7 |
| abstract_inverted_index.hmAbs | 218 |
| abstract_inverted_index.human | 103, 109, 176 |
| abstract_inverted_index.panel | 101 |
| abstract_inverted_index.serum | 131, 189 |
| abstract_inverted_index.shown | 211 |
| abstract_inverted_index.their | 135 |
| abstract_inverted_index.(ScFv) | 162 |
| abstract_inverted_index.(hmAb) | 106 |
| abstract_inverted_index.Africa | 182 |
| abstract_inverted_index.Pfs230 | 83 |
| abstract_inverted_index.assays | 251 |
| abstract_inverted_index.assess | 187, 254 |
| abstract_inverted_index.called | 62 |
| abstract_inverted_index.cells. | 80 |
| abstract_inverted_index.deaths | 11 |
| abstract_inverted_index.define | 164 |
| abstract_inverted_index.gamete | 69 |
| abstract_inverted_index.global | 26 |
| abstract_inverted_index.higher | 20 |
| abstract_inverted_index.levels | 201 |
| abstract_inverted_index.manner | 91 |
| abstract_inverted_index.puzzle | 34 |
| abstract_inverted_index.stages | 50 |
| abstract_inverted_index.target | 47 |
| abstract_inverted_index.trials | 179 |
| abstract_inverted_index.(SMFA). | 150 |
| abstract_inverted_index.627,000 | 9 |
| abstract_inverted_index.Efforts | 16 |
| abstract_inverted_index.Further | 228 |
| abstract_inverted_index.Methods | 95 |
| abstract_inverted_index.Pfs230, | 65 |
| abstract_inverted_index.Results | 151 |
| abstract_inverted_index.against | 82 |
| abstract_inverted_index.assayed | 185 |
| abstract_inverted_index.between | 215 |
| abstract_inverted_index.binding | 74, 166, 191, 223 |
| abstract_inverted_index.complex | 32 |
| abstract_inverted_index.current | 59 |
| abstract_inverted_index.develop | 18, 121 |
| abstract_inverted_index.efforts | 244 |
| abstract_inverted_index.feeding | 149 |
| abstract_inverted_index.gametes | 87 |
| abstract_inverted_index.include | 41 |
| abstract_inverted_index.leading | 60, 263 |
| abstract_inverted_index.malaria | 6, 10, 22 |
| abstract_inverted_index.million | 5 |
| abstract_inverted_index.protein | 71 |
| abstract_inverted_index.surface | 70 |
| abstract_inverted_index.targets | 64 |
| abstract_inverted_index.vaccine | 23, 36, 39, 257 |
| abstract_inverted_index.Abstract | 0 |
| abstract_inverted_index.Authors: | 267 |
| abstract_inverted_index.Pfs230D1 | 225 |
| abstract_inverted_index.antibody | 190 |
| abstract_inverted_index.antigen. | 226 |
| abstract_inverted_index.blocking | 43 |
| abstract_inverted_index.competed | 194 |
| abstract_inverted_index.effector | 138 |
| abstract_inverted_index.efficacy | 21, 258 |
| abstract_inverted_index.features | 136, 239 |
| abstract_inverted_index.mediates | 73 |
| abstract_inverted_index.membrane | 148 |
| abstract_inverted_index.mosquito | 49 |
| abstract_inverted_index.occurred | 12 |
| abstract_inverted_index.parasite | 52, 56 |
| abstract_inverted_index.presence | 198 |
| abstract_inverted_index.quantify | 129 |
| abstract_inverted_index.received | 112 |
| abstract_inverted_index.reported | 269 |
| abstract_inverted_index.standard | 147 |
| abstract_inverted_index.vaccines | 44 |
| abstract_inverted_index.variable | 160 |
| abstract_inverted_index.developed | 157 |
| abstract_inverted_index.estimated | 3 |
| abstract_inverted_index.expanding | 140 |
| abstract_inverted_index.fragments | 161 |
| abstract_inverted_index.generated | 107 |
| abstract_inverted_index.interrupt | 55 |
| abstract_inverted_index.parasites | 29 |
| abstract_inverted_index.platform. | 125 |
| abstract_inverted_index.priority, | 27 |
| abstract_inverted_index.worldwide | 13 |
| abstract_inverted_index.Alhydrogel | 116 |
| abstract_inverted_index.Antibodies | 81 |
| abstract_inverted_index.Background | 1 |
| abstract_inverted_index.Conclusion | 227 |
| abstract_inverted_index.Innovative | 38 |
| abstract_inverted_index.Plasmodium | 67 |
| abstract_inverted_index.adjuvants, | 119 |
| abstract_inverted_index.antibodies | 105, 132, 168 |
| abstract_inverted_index.biological | 33 |
| abstract_inverted_index.correlates | 255 |
| abstract_inverted_index.durability | 260 |
| abstract_inverted_index.exploiting | 99 |
| abstract_inverted_index.falciparum | 68 |
| abstract_inverted_index.formulated | 114 |
| abstract_inverted_index.functional | 144 |
| abstract_inverted_index.functions, | 139 |
| abstract_inverted_index.monoclonal | 104 |
| abstract_inverted_index.saturating | 200 |
| abstract_inverted_index.strategies | 40 |
| abstract_inverted_index.vaccinated | 172 |
| abstract_inverted_index.volunteers | 110, 177 |
| abstract_inverted_index.Disclosures | 265 |
| abstract_inverted_index.Preliminary | 204 |
| abstract_inverted_index.antibodies. | 242 |
| abstract_inverted_index.competition | 214 |
| abstract_inverted_index.competitive | 123, 153, 208 |
| abstract_inverted_index.development | 53 |
| abstract_inverted_index.foundations | 248 |
| abstract_inverted_index.Pfs230D1-EPA | 63, 113 |
| abstract_inverted_index.characterize | 234 |
| abstract_inverted_index.confirmation | 220 |
| abstract_inverted_index.development. | 37 |
| abstract_inverted_index.disclosures. | 270 |
| abstract_inverted_index.individuals. | 173 |
| abstract_inverted_index.microgametes | 76 |
| abstract_inverted_index.optimization | 205, 229 |
| abstract_inverted_index.single-chain | 159 |
| abstract_inverted_index.standardized | 250 |
| abstract_inverted_index.transmission | 42 |
| abstract_inverted_index.transmission. | 57, 94 |
| abstract_inverted_index.conventionally | 142 |
| abstract_inverted_index.epitope-specific | 130, 165, 188, 213, 241 |
| abstract_inverted_index.complement-binding | 236 |
| abstract_inverted_index.complement-dependent | 90 |
| abstract_inverted_index.concentration-dependent | 212 |
| abstract_inverted_index.isotype/subclass-specific | 238 |
| cited_by_percentile_year | |
| countries_distinct_count | 1 |
| institutions_distinct_count | 5 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.8199999928474426 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.25179655 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |